We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. We have developed a proprietary product engine that we employ to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat the known root cause of genetically defined diseases. We are using our product engine to identify targets that can be drugged by small molecules regardless of the particular underlying mechanism of gene mis-expression. We have identified drug targets to treat the root causes of facioscapulohumeral muscular dystrophy (FSHD) and certain hemoglobinopathies, namely sickle cell disease (SCD) and b-thalassemia.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Jun 24, 2021
Jun 21, 2021
May 12, 2021
More events are coming soon.